IL-1 blockers, such as Anakinra (and possibly mAb Kanakinumab), may be an additional weapon against the respiratory distress syndrome in COVID-19, in view of its effectiveness in patients with severe forms of sepsis and with an inflammatory profile resembling the “macrophage activation syndrome” (MAS) [53,54]. This evidence concerns the gene IL1B and macrophage activation syndrome.